DxS and Epigenomics Cross-License Technology for In Vitro Diagnostics
The cross-licensing follows a strategic agreement signed by both companies in January 2008. Under the terms of this agreement, Epigenomics had obtained worldwide non-exclusive rights to DxS' Scorpions technology for R&D use and research kits, as well as an option to expand the license to the in vitro diagnostics field. In return, DxS received an option for a worldwide non-exclusive research and IVD license to certain Epigenomics IP covering the use of Scorpions technology for DNA methylation applications. Both companies have now executed their options as granted in last years agreement and have acquired the right to sub-license the respective licensed technologies.
Financial terms of the agreement were not disclosed.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.